Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
In this article
Pharma thinks it’s found the next frontier in preventing heart attacks.
Novartis
, Amgen
and Eli Lilly
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound…
Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in…
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference…
Amgen CEO Bob Bradway told CNBC's Jim Cramer about his company's treatment to reduce heart attack risk.
Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the…
